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Background: Sepsis-like illness is a main cause for hospital admission in young infants. Our 
aim was to investigate incidence, epidemiology and clinical characteristics of enterovirus (EV) 
and human parechovirus (HPeV) infections in young infants with sepsis-like illness. 
Methods: This is a prospective observational cohort study in which infants younger than 90 days 
of age, presenting with sepsis-like symptoms in a secondary care children’s hospital, underwent 
a full sepsis work-up. Clinical signs and infectious indices were recorded. EV or HPeV RNA was 
detected by PCR in plasma and/or cerebrospinal fluid (CSF). 
Results: Infants were diagnosed with EV, HPeV, fever of unknown origin or severe infection. 
EV and HPeV were detected in 132/353 (37%) and 52/353 (15%) of cases, respectively. EV and 
HPeV have distinct seasonability. Some differences in clinical signs and symptoms occurred 
between children with EV and HPeV infection, but were of limited clinical value. CSF 
pleocytosis occurred in 44% of EV positive infants, and only in 13% of those with HPeV 
infection. 
Conclusions: EV and HPeV infections are major causes of sepsis-like illness in infants < 90 
days of age. Neither clinical characteristics nor laboratory indices were predictive for EV/HPeV 
infection. CSF pleocytosis occurs, but not in all patients. Testing for EV and HPeV in all young 





































































Sepsis-like symptoms in children, especially in young infants (under 90 days of age) remain a 
diagnostic challenge for pediatricians because it is often hard to distinguish between serious 
bacterial infections and more benign viral infections1 2. 
In young infants enterovirus (EV) and human parechovirus (HPeV) infections are a known cause 
of sepsis-like illness, aseptic meningitis and febrile disease3-6. Numerous EV-types, specifically 
several serotypes of the enterovirus B species, have been associated with febrile-illness and 
aseptic meningitis in infants7 8. In HPeV-infection, type 3 (HPeV3) is the main genotype causing 
sepsis-like symptoms in young infants9 10. EV and HPeV infections can also cause serious 
symptoms such as cardiorespiratory instability and neurologic symptoms, leading to hospital or, 
in some young infants, pediatric intensive care unit admittance11-14. 
Previous studies have reported a high incidence of EV and HPeV infections among febrile 
infants, but most were retrospective15 16, based on laboratory17-19 results rather than clinical 
presentation, did not solely focus on young infants3 or described neonates only6. Only one 
prospective cohort that included patients up to 90 days of age was described earlier5. 
We performed a prospective observational cohort study to describe epidemiology, clinical 
characteristics and infectious indices of young infants with sepsis-like illness who presented at 
our emergency department. Our hypothesis is that EV and HPeV are a major cause of sepsis-like 
illness in this vulnerable group of infants up to 90 days of age and that symptoms of infants with 
EV or HPeV infection are not different from other infants with sepsis-like illness. Main outcome 
is frequency of diagnosis of EV or HPeV infection in our study population, secondary outcomes 




































































Materials and Methods 
Study protocol – clinical aspects 
This prospective observational cohort study was performed at the Juliana Children’s Hospital, 
The Hague, Netherlands. All children under 90 days of age who were evaluated at our emergency 
department for sepsis-like symptoms between January 1, 2008 and June 30, 2012 were evaluated 
in this study. Sepsis-like illness was diagnosed based on age-specific criteria (see table, 
Supplemental Digital Content 1), which were evaluated at physical examination by the attending 
physician. All physicians in our hospital were trained in their use. In addition to the clinical signs 
and symptoms described in Supplemental Digital Content 1 (table), the following clinical 
parameters were collected: sex, prematurity (gestational age < 37 weeks), medical history, 
abnormal behavior (defined as lethargic or agitated), skin rash, oxygen saturation at presentation 
and duration of symptoms before presentation. If a specific symptom was not clearly noted on 
admittance, this item was labeled as ‘missing’. 
We excluded patients with signs of a localized infection, defined as clinically apparent gastro-
enteritis, upper respiratory tract infection, pneumonia (clinically apparent and confirmed on chest 
x-ray) or abnormal analysis of urine sediment (more than five white blood cells (WBC) per
microscopic field view, magnification of 40 times). 
Patients with need of systemic intravenous treatment for a confirmed (with bacterial culture or 
HSV PCR) pathogen were assigned to the group ‘severe infection’. Patients with insufficient 
sample size of both plasma and cerebrospinal fluid (CSF) to perform PCR for EV and HPeV 
were labelled as ‘non-evaluable result’. To investigate whether or not these patients influenced 
our results, we performed additional analyses including them once in the EV or HPeV group and 





































































Biochemical and microbiologic data 
Children underwent blood and CSF sampling for biochemical analysis, viral analysis for EV and 
HPeV, and bacterial cultures. Herpes simplex virus PCR was performed on CSF.  
The results for C-reactive protein, serum glucose, full blood count, and WBC differentiation 
were recorded. When CSF was successfully collected, CSF white and red blood cell counts, CSF 
glucose and protein levels were recorded in the study database. We corrected CSF WBC count 
for traumatic puncture if the CSF red blood cell count was > 1000 cells/μL, using a 1000:1 
ratio22. CSF pleocytosis was defined as a CSF WBC count > 19 cells/μL for children <28 days of 
age, >9 cells/μL for children 28-58 days of age and >5 cell/ μL for children 59-90 days of age 23 
24.  
 
EV and HPeV detection and genotyping 
PCR was performed on plasma and CSF to detect EV or HPeV RNA. RNA was extracted from 
200 μL of plasma and/or 50-200 μL of CSF with the Nuclisens easyMAG system (Biomerieux, 
Boxtel, Netherlands). The manufacturer’s protocol (Generic 1.0) was followed using easyMAG 
specific reagents. A fixed amount of Phocine Distemper Virus served as an internal control and 
was added to each sample prior to RNA extraction. Extracted RNA was used for Reverse 
Transcription PCR to synthesize copy DNA and PCR was performed with the ABI 7500 Real 
Time PCR system (Applied Biosystems, USA): 10 minutes at 95 °C, followed by 45 cycles of 15 
sec at 95°C, and 1 minute at 60°C. Primers and probes for amplification and detection of EV and 
HPeV were located in the highly conserved 5’end of the genome. Modifications were made to 





































































VIC-CCCCAGATCAGATCC-MGB and primers were adjusted to 
TGCAAACACTAGTTGTAAGGCCC, TGCAGACACTAGTTGTAAGGCCC, 
TGCAAACACTAGTTGTATGGCCC (forward primers) and 
TTGGCCCACTAGACGTTTTTTAA, TTGGCCCGCTAGACGTTTTTTAA, 
GTTTGGCCCACTAGACGTTTTT (revers primers).  
All PCR runs had a mixture of an EV and HPeV strain as a positive control and nuclease free 
water as a negative control.  
A positive diagnosis for infection with EV or HPeV was made on a positive PCR in either 
plasma or CSF (or both).  
EV and HPeV positive plasma and CSF samples were genotyped in one batch after completion 
of the study period if enough material was left. EV typing was performed as previously described 
with modifications28. In short, two PCR’s were run (EV-A and EV-B) for which 6 μL of input 
RNA was used. The original protocol was adjusted to perform a semi-nested PCR instead of a 
single PCR19. PCR-1 was performed using primers (EV-A OS 2268 + EV-A OAS 3109 and EV-B 
OS 2324 + EV-B OAS 3505) for 1 hour at 43°C, followed by 2 x 20 cycles at 53 and 55°C, 15 
minutes at 72°C, and 2 minutes at 94°C. Thereafter, 3 x 40 cycles were performed at 94°C, 50°C 
and 68°C, followed by 5 minutes at 68°C. One μL of this fluid was then transferred to PCR-2 
with primers (EV-A OS 2268 + EV-A IAS 3016 and EV-B OS 2324 + EV-B IAS 3477). This was 
processed in 3 x 30 cycles (18 min at 94°C, 21 min at 55°C and 90 min at 72°C), followed by 5 
min at 72°C. Fluid of PCR-2 (5-10 μL) was loaded on an agarose gel, if positive (band visible of 
750bp (EV-A) or 1150bp (EV-B)), a standard BDT sequence reaction was performed using 



































































HPeV typing was performed as previously described by Harvala et al19. One modification was 
made; we used a different OS primer (HPeV OS-R-2162; TCMACWTGGATGAGGAARAC 
instead of the original primer HPeV OS-2090) in PCR-1. 
Statistical analysis 
SPSS was used for data management (PASW statistics version 17.0) and statistical analysis (IBM 
SPSS statistics version 23.0). Data were checked for normality before analysis, using descriptive 
statistics and histograms with z-scores for skewness and kurtosis. Categorical data are shown as 
absolute number/total (percentage) and numerical data as median (interquartile range). 
P-values <0.05 were considered to indicate statistical significance, in subgroup analyses we
considered p-values <0.01 statistically significant. Mann-Whitney-U tests and Kruskal Wallis 
tests were used for numerical data and Fisher’s Exact tests for categorical data. Binary logistic 
regression analysis was performed to assess the relationship between the occurrence of EV or 
HPEV infection or FUO (dependent variable) and clinical characteristics or laboratory 
parameters (independent variables). 
The data described in our study were derived from our standard of care. No extra interventions 
were conducted for study purposes only. Therefore, no explicit informed consent from parents 
was warranted for this study. The personal data of our patients were protected. The study was 
approved by the regional medical ethics committee. 
Results 
During the study period 362 infants with sepsis-like illness were included. Nine infants (2%) 




































































and HPeV PCR. The additional analyses to investigate the influence of these non-evaluable 
patients to our cohort showed no change in our results (data not shown).  
 
Epidemiology 
The remaining 353 infants were diagnosed as: EV-infection (n=132 (37%)), HPeV infection 
(n=52 (15%)), fever of unknown origin (FUO) (n=162 (46%)) and severe infection (n=7 (2%)). 
Details of the recruitment and diagnoses of our cohort and the causative pathogens of infants in 
the ‘severe infection’ group are given in figure 1.  
Figure 2 shows the seasonal distribution of the different diagnoses. During summer, there is a 
yearly peak of EV infection and biannual peak of HPeV infections in even years. During winter 
2009 an increase in FUO occurred during the influenza A (H1N1) pandemic in our country. 
Bacterial infections occurred with a low incidence throughout the study period.  
 
Viral genotyping 
Enough material was available to perform genotyping in 35/184 EV or HPeV positive infants 
(19%). Genotyping was possible for 23/132 (17%) EV positive patients, of whom 22 were 
enterovirus-B positive (CV-B1, CV-B2, CV-B4, CV-B5, E-6, E-7, E-9, E-11, E-18, E-25, and E-
30) and 1 enterovirus-A (CV-A16) positive. This infant presented with sepsis-like illness, was 
EV positive in plasma and negative in CSF, and did not develop any signs of hand-foot-mouth 
disease during its hospital stay. Supplemental Digital Content 2 (table) shows the details of EV 






































































Clinical and biochemical parameters 
Clinical symptoms, vital parameters and infectious parameters of our study population are 
presented in Table 1 and 2. No statistically significant differences occurred between the serious 
bacterial infections group and the FUO and ‘EV or HPeV’ group.  
Comparing the EV or HPeV group to the FUO group showed that infants in the EV or HPeV 
positive group were more often less than 28 days of age (p=0.003) and showed statistically 
significant, but only slightly higher heart and breathing frequencies at presentation compared to 
patients in the FUO group. There also was a difference in behavior (p=0.006) and children with 
EV or HPeV had somewhat lower infectious parameters (p<0.01). Comparing EV/HPeV positive 
infants to those in the FUO group, logistic regression showed differences in age-group (0-28 
days or 29-90 days) (OR 0.243 (95% CI 0.101-0.584)), plasma WBC count (OR 0.743 (95% CI 
0.601-0.919)) and CSF WBC count (OR 1.009 (95% CI 1.002-1.015).  
Table 2 compares between EV and HPeV positive infants. HPeV positive infants have a lower 
rate of CSF pleocytosis (8%) than EV positive infants (43%) (p=0.000) and have somewhat 
lower infectious indices than infants with an EV infection. 
 No children were transferred to a pediatric intensive care unit and none died. All children visited 
our outpatient clinic 4-6 weeks after hospital admittance. None of them showed any physical 
abnormalities at this follow-up visit.  
 
Discussion 
We describe a high incidence of EV and HPeV infection in the largest prospective cohort study 




































































laboratory signs, and symptoms of sepsis-like illness in young infants, especially those with an 
EV or HPeV infection.  
Several laboratory-based and retrospective studies have identified EV and HPeV as an important 
cause of sepsis and/or meningitis in young infants 9 10 29-31. Rittichier et al. showed, in a 
prospective study, an incidence of 20% of EV infection in young infants with fever who 
underwent a full sepsis work-up5. We find a higher incidence of EV infection (36%), this may be 
due to our selection of a population with a higher risk, as we only included those infants with 
sepsis-like illness instead of all infants with fever. Cabrerizo et al. recently reported an incidence 
of 38% for EV infection and 11% for HPeV infection in neonates with fever, sepsis or 
meningitis6. We describe similar incidences, but in a population up to 90 days of age, instead of 
only neonates, adding to the importance of EV and HPeV testing in this group.  
In contrast, in previous laboratory-based reports, the incidence of EV and HPeV infections was 
much lower10 12 30. For example, Wolthers et al. detected EV in 14% and HPeV in 4.6% of 
cerebrospinal fluid (CSF) samples of young children (median age 1 month) with sepsis-like 
illness and meningitis during a 3-year period30. The lower frequencies found in this study may be 
attributed to the retrospective analysis of randomly submitted samples instead of samples taken 
prospectively in a selected patient group, as well as the difference in age groups. Also, we tested 
both plasma and CSF, instead of CSF only.  
We made minor modifications to PCR methods described previously25-27, to also detect HPeV3. 
With this method, detection rate was similar to or higher than previous reports, and genotyping 
showed only HPeV3, confirming the accuracy of the adjustments.  
In Europe HPeV3 occurs in a biannual cycle with a peak in even-numbered years 30 32. We also 



































































illness. In our population, the incidence of HPeV in epidemic years increased sharply to 19% in 
2008, 26% in 2010 and 27% in 2012, and in non-epidemic years dropped to about 2% (both in 
2009 and 2011), but HPeV was never completely absent. The higher detection rate of HPeV, 
which is presumably mainly HPeV3, is most probably due to the heightened awareness of HPeV 
as a pathogen and subsequent implementation of HPeV3 specific PCR methods just before our 
study period32. 
Because of low sample volumes viral typing was possible only in part of our population, we 
were able to type 23/132 (17%) of the EV and 12/52 (23%) of the HPeV positive infants. 
As expected, in the 23 EV positive patients we found a wide variety of genotypes, all but one 
were Enterovirus B genotypes. E-5, 6, 11 and 30, and CV-B5, B4 and B1 have been reported to 
cause sepsis-like illness in young infants16 29 33 34. However this is the first description of E-7, 18 
and 25, and CV-B4 to cause sepsis-like illness in infants. 
In addition, we are the first to report a CV-A16 related to sepsis-like illness in infants35. CV-A16 
has caused outbreaks of  hand-foot-mouth disease36 and rare complications, such as aseptic 
meningitis or pulmonary edema have been described in Asia37. It has also been described as a 
rare cause of fatal infection in infants, with only 4 cases described worldwide38-41. 
All of the typed HPeV positive infants were HPeV3 positive. This is concordant with previous 
reports that describe HPeV3 as a main pathogen for sepsis-like illness and aseptic meningitis in 
young infants9. Although we could only test 23% of our study population, we only found HPeV3 
and therefore consider this the main HPeV type causing illness in our patient group. Other HPeV 




































































Although differences between infants with EV or HPeV and those with FUO (table 1 and 2) were 
statistically significant, most likely due to the large sample size of our population, they have a 
very limited clinical value because the differences of the variables are small and overlapping. It 
is interesting to notice, however that the infectious indices of HPeV infected infants are 
somewhat lower than those of infants with EV infection. The clinical presentation of infants with 
EV and HPeV infection was similar, as has been reported previously11. 
In our study we show that although pleocytosis is uncommon in HPeV infection (8%) compared 
to EV infection (43%), it is not absent. Recently, Cabrerizo et al. described 32 EV positive and 9 
HPeV positive neonates and found no CSF pleocytosis in those with an HPeV infection. EV 
positive patients showed pleocytosis in 19/32 (59%) of cases6. Yun et al. showed that EV 
meningitis occurred without pleocytosis in 68% of neonates.  Absence of CSF pleocytosis was 
associated with a younger age and a shorter time period between onset of disease and lumbar 
puncture44. In accordance with this study, we evaluated a group of very young patients, in whom 
a lumbar puncture was performed shortly after onset of disease (median, 0.5 days), and find a 
low number of pleocytosis and high incidence of EV or HPeV (tables 1 and 2). Several studies 
have reported EV and HPeV positive children without CSF pleocytosis who developed neonatal 
seizures or cerebral white matter abnormalities13 14 30. More research is required to elucidate 
whether or not CSF pleocytosis is associated with severity of disease, cerebral white matter 
involvement and neurologic sequelae in children with EV and HPeV infections. Testing for EV 
and HPeV, even in absence of pleocytosis, should be considered standard of care. 
Our study has its limitations. We only tested for the presence of EV and HPeV on blood and CSF 
and did not perform tests to discover viral infections other than EV, HPeV, and herpes simplex 




































































dual infections of infants with an EV or HPeV infection. Our objective was to identify the impact 
of EV and HPeV on sepsis-like illness in our population of young infants and this lack of testing 
for other viruses did not influence our outcome. But it would be of interest for further research.  
 
This study adds a large prospective cohort of young infants with sepsis-like illness to current 
knowledge. We describe similar findings in epidemiology, with a higher detection rate than 
previously reported, of HPeV in epidemic years. And although less common than in EV 
infection, HPeV can cause pleocytosis and aseptic meningitis. Testing for EV and HPeV in 
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Figure 1: Flowchart of study population and details of diagnoses in the ‘severe infection’ 
subgroup.  
 
Figure 2: Seasonal distribution per diagnosis 
Legend: black = EV; dotted = HPeV; dark gray = severe infection; light gray = FUO. 
 
SDC Legend: 
SDC 1. Criteria for sepsis-like illness according to age.doc 










































































EV or HPeV* 
(EV, n=132, 37%) 
(HPeV, n=52, 15%)  
FUO*  
(n=161, 46%)  
 
p-value 
Sex (males) 6/8 (75%) 116/184 (62%) 85/161 (52%) 0.063 
Positive Medical 
History 
1/8 (13%) 9/184 (5%) 10/161 (6%) 0.641 
Prematurity 1/6 (17%) 6/165 (5%) 7/148 (5%) 1.000 
Age <28 days 4/8 (50%) 101/184 (55%)* 62/161 (39%)* 0.003 
Rash  2/8 (25%) 29/178 (16%) 23/154 (15%) 0.764 
Body temperature 
(0C)  
38.7 (38.0-39.1) 38.7 (38.3-39.1)* 38.5 (38.1-38.9)* 0.001 
Heart Frequency 
(/min) 
164 (147-187) 172 (158-188)* 167 (150-180)* 0.007 
Breathing frequency 
(/min) 
37 (32-56) 50 (40-60)* 44 (35-52)* 0.001 
Oxygen Saturation 
(%) 
99 (97-100) 100 (98-100) 99 (98-100) 0.134 
Capillary refill >2 
sec (%)  
3/7 (43%) 46/177 (26%) 32/155 (21%) 0.299 
Abnormal behaviour 5/8 (63%) 140/182 (77%)* 102-161 (63%)* 0.006 
Duration of illness 
before presentation 
0.5 (0.1-2.5) 0.5 (0.5-1.0) 0.5 (0.5-1.5)  0.450 
White blood cell 
count (x109/L)  
14.0 (3.9-18.5) 7.7 (5.6-10.1)* 10.1 (8.0-14.3)* 0.000 
Blood neutrophil 
count (x109/L) 






22 (7-41) 6 (3-20) 6 (3-19) 0.964 
Pleocytosis (%) 3/8 (38%) 51/152 (34%) 17/91 (19%) 0.013 
CSF white blood cell 
count (x/3µL) 
13 (5-359) 8 (2-58)*  3 (2-11)* 0.003 
CSF glucose 
(mmol/L) 
2.4 (1.0-3.1) 2.9 (2.6-3.3) 3.1 (2.8-3.3) 0.044 
CSF protein  (mg/L) 0.79 (0.55-1.58) 0.54 (0.41-0.72) 0.49 (0.34-0.68) 0.087 
 
p-values <0.01 were considered to indicate statistical significance (subgroup analysis) 
Mann-Whitney-U tests were used for numerical data and Fisher’s Exact tests for 
categorical data.  
^ No statistically significant difference existed between the severe infection and other 
subgroups.  
* p-values indicate a difference between the ‘EV or HPeV’ and ‘FUO’ groups. 
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Table 2: Comparison of EV and HPeV positive infants 
EV (n=132) HPeV (n=52) p-value
Sex (males) 84/132 (64%) 32/52 (62%) 0.866 
Positive Medical History 7/132 (5%) 2/52 (4%) 1.000 
Prematurity 5/126 (4%) 4/48 (8%) 0.263 
Age <28 days 77/132 (58%) 24/52 (46%) 0.143 
Rash 19/127 (15%) 10/51 (20%) 0.502 
Body temperature (0C) 38.6 (38.3-38.9) 38.8 (38.3-39.1) 0.223 
Heart frequency (/min) 170 (156-185) 182 (161-195) 0.012 
Breathing frequency (/min) 50 (40-60) 48 (40-59) 0.447 
Oxygen Saturation (%) 100 (98-100) 100 (98-100) 0.469 
Capillary refill >2 sec (%) 28/128 (22%) 18/49 (37%) 0.055 
Abnormal behaviour 96/131 (73%) 44/51 (86%) 0.078 
Duration of illness before 
presentation 
0.5 (0.5-2.0) 0.5 (0.25-1.0) 0.013 
White blood cell count (x109/L) 8.2 (6.6-10.8) 5.2 (4.0-8.1) 0.000 
Blood neutrophil count (x109/L) 4.0 (2.7-5.1) 2.3 (1.6-3.6) 0.000 
C-Reactive Protein (mg/L) 8 (3-24) 5 (2-9) 0.027 
Pleocytosis (%) 48/113 (43%) 3/39 (8%) 0.000 
CSF white blood cell count (x/3µL) 13 (3-151) 4 (2-9) 0.001 
CSF glucose (mmol/L) 2.8 (2.6-3.2) 3.2 (2.9-3.4) 0.000 
CSF protein  (mg/L) 0.54 (0.43-0.74) 0.47 (0.38-0.64) 0.149 
P-values <0.01 were considered to indicate statistical significance (subgroup analysis).





















HSV encephalitis (n=1), 
Gr.B Streptococcus 
(sepsis n=1, meningitis (n=2)), 
E. Coli meningitis (n=1), 
Klebsiella spp. Urosepsis
(negative urine sediment) (n=1), 














SDC 1: Criteria for sepsis-like illness according to age* 
Age at presentation 0-28 days 1-3 months
Clinical signs and 
symptoms  
One or more: 
- toxic appearance
- temp <36.0 oC or >38.0 oC
- feeding problems
- lethargy or agitation
- tachypnea
- tachycardia
- capillary refill > 2 sec
One or more: 
- toxic appearance
- temp <36.0oC or >39.0oC
- fever >48 hours
- lethargy or agitation
- capillary refill >2 sec
- bulging fontanel
Criteria for toxic 
appearance 
Rochester Criteria20 Yale observation scale21 > 10 
* Local adaptation of national guidelines for management of children with fever without
source (Dutch Association of Paediatrics, NvK). 
SDC 1 table Click here to download Supplemental Digital Content (Including
Separate Legend) 217-23 SDC 1 table.docx
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SDC 2: Enterovirus serotyping details  
Species Serotype Number of 
Patients 
Season/year of diagnosis 
Entero B E-25 3 Winter, Spring, and Summer 2008  
Entero B E-7 1 Summer 2008  
Entero B CV-B4 1 Summer 2008 
Entero B CV-B1 2 Summer and Autumn 2008 
Entero B E-9 3 Summer and Autumn 2009  
Entero B CV-B5 3 Winter, Spring and Summer 2009  
Entero B E-6 2 Summer 2009 
Entero B E-11 2 Winter 2009 and Summer 2010 
Entero B CV-B2 2 Summer and Autumn 2010 
Entero B E-30 2 Summer 2010 and Winter 2011 
Entero A CV-A16 1 Autumn 2010 
Entero B E-18 1 Summer 2012 
 
SDC 2 table Click here to download Supplemental Digital Content (Including
Separate Legend) 217-23 SDC 2 table.docx
